WLFI price prints a bearish SFP after sweeping major liquidity at the swing high, signalling increased downside risk if price fails to reclaim key value area levels.WLFI price prints a bearish SFP after sweeping major liquidity at the swing high, signalling increased downside risk if price fails to reclaim key value area levels.

WLFI price rejects after liquidity grab, bearish SFP emerges

WLFI price prints a bearish SFP after sweeping major liquidity at the swing high, signalling increased downside risk if price fails to reclaim key value area levels.

Summary
  • WLFI’s recent rejection shows fading bullish strength after an aggressive liquidity sweep.
  • Current positioning below $0.16 keeps sellers in control of short-term direction.
  • A move into $0.12 would provide the next major reaction zone for traders.

World Liberty Financial (WLFI), the Trump family’s crypto firm, has delivered a sharp rejection after sweeping liquidity above its recent swing high, forming a clear bearish Swing Failure Pattern. This development follows an impulsive rally from the predetermined $0.11 support, but momentum has now shifted as sellers step in aggressively. 

Crypto tensions are climbing in Washington, with senators now demanding a probe into World Liberty Financial, adding further uncertainty around the asset’s short-term trajectory. The evolving structure places the focus on value area levels that will determine whether WLFI extends lower or manages a reclaim to regain bullish footing.

WLFI price key technical points

  • Bearish SFP confirms a failed breakout, placing pressure on WLFI as trapped longs unwind.
  • Value area high at $0.16 acts as the decisive pivot, where a breakdown signals continuation to the downside.
  • High-time-frame support at $0.12 is the next major target, marking a key reaction zone if bearish momentum persists.
WLFI price rejects after liquidity grab, bearish SFP emerges - 1

WLFI’s recovery from $0.11 initiated a strong surge toward the previous swing high, but the move quickly showed signs of exhaustion. Once liquidity was taken above that high, price immediately reversed, forming a textbook Swing Failure Pattern, a signal that buyers failed to sustain the breakout and were likely absorbed by larger-time-frame sellers. This has shifted sentiment and structure toward a more cautious, bearish outlook.

The region around $0.16, representing the value area high, is now the defining level in the short term. As long as WLFI trades beneath this threshold, the SFP remains fully active and downside continuation remains the higher-probability scenario.

A reclaim would significantly weaken the bearish case, but order flow suggests buyers remain hesitant while sellers reclaim control of the chart. Volume during the rejection further supports the view that the SFP is not a minor deviation but a meaningful structural break.

If WLFI remains capped below the SFP zone and value area high, the next logical target becomes the high-time-frame support near $0.12. This region previously acted as a critical base for upward expansion and represents the strongest demand zone locally.

A move into this area would not be unexpected, especially considering the impulsive nature of the rejection and the broader market’s tendency to retest major supports following liquidity grabs.

What to expect in the coming price action

If WLFI cannot reclaim the $0.16 value area high, bearish continuation into $0.12 remains the most probable outcome. A strong reclaim of the SFP region would be required to invalidate this downside trajectory.

Market Opportunity
WLFI Logo
WLFI Price(WLFI)
$0.17
$0.17$0.17
-1.73%
USD
WLFI (WLFI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26